Viruses as Therapeutic Agents for Cancer

Erscheinungsjahr 2026
ISBN: 978-0-443-43236-1
Verlag: Elsevier Science & Technology

Buch, Englisch, Format (B × H): 152 mm x 229 mm, Gewicht: 450 g

Viruses as Therapeutic Agents for Cancer, Volume 171 in the Advances in Cancer Research series, highlights new advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including Coxsackievirus virotherapy, Oncolytic reovirus, Cancer immunotherapy with oncolytic myxoma virus, Zika Virus as an Oncolytic Therapy, Nonreplicative adenoviral vectors for cancer, VSV Oncolytic Virotherapy, AAV vectors for cancer gene therapy, Adenovirus cancer vaccines, Advancing Clinical Translation of Oncolytic Adenoviruses, and Immunotherapuetic Cancer Terminator Viruses.

Autoren/Hrsg.

Weitere Mitwirkende

Tew, Kenneth D.

Curiel, David T.

Fachgebiete

• Naturwissenschaften Biowissenschaften Zellbiologie
• Naturwissenschaften Biowissenschaften Biowissenschaften Genetik und Genomik (nichtmedizinisch)
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie
• Naturwissenschaften Biowissenschaften Mikrobiologie

Inhaltsverzeichnis

1. Coxsackievirus virotherapy
Vinod E. Nambudiri
2. Oncolytic reovirus
Kenny Voon and Zhen Yun Siew
3. Cancer immunotherapy with oncolytic myxoma virus
Masmudur M. Raham, Jacqueline Carmona and Deon Nguyen
4. Zika Virus as an Oncolytic Therapy
Eric Hawley and Milan Chheda
5. Nonreplicative adenoviral vectors for cancer
Bryan E. Strauss, Ana Laura Vieira Alves, Bianca Naomi Niitsuma, Fernanda Antunes, Jean Carlos dos Santos da Luz, Mariana Barbosa de Souza and Soraia Barbosa de Oliveira
6. VSV Oncolytic Virotherapy
Jennifer Altomonte
7. AAV vectors for cancer gene therapy
Myungeun Lee, Jinhyun Park and Ji Hoon Park
8. Adenovirus cancer vaccines
Vinnycius Pereira Almeida
9. Advancing Clinical Translation of Oncolytic Adenoviruses
Julia Davydova and Margarita Romanenko
10. Immunotherapuetic Cancer Terminator Viruses
Paul B. Fisher

Über Autor(innen)

Tew, Kenneth D.
Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.

Curiel, David T.
David T. Curiel, M.D., Ph.D. is the Director of the Cancer Biology Division of the Department of Radiation Oncology at Washington University School of Medicine. Dr. Curiel graduated medical school at Emory University in 1982, where he also completed his internship and residency in Internal Medicine. Dr. Curiel’s scientific training includes tenureship at the National Institutes of Health in Bethesda, Maryland at the Pulmonary Branch of the Heart and Lung, and Blood Institute (NHLBI) from 1985-1989, and a fellowship in Biotechnology at the National Cancer Institute, Navy Medical Oncology Branch from 1989-1990. He received his Ph.D. from University of Groningen in The Netherlands in 2002. Dr. Curiel has been at Washington University School of Medicine since 2011. In addition to his role as Director of the Cancer Biology Division, he is Director of the Biologic Therapeutics Center.